Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2014

View Archived Issues

Voyant Biotherapeutics and Allergan enter R&D agreement in ocular disease

German group patents novel antibodies for Plasmodium infections

Unbiased screening of chemotherapeutic agents used to uncover novel indications for existing drugs

Japanese researchers present new agents for neurological disorders and cancer

Discovery of a novel variant in a gene of unknown function associated with fatty liver disease

SCY-078 receives QIDP designation from the FDA

EMA concludes review of Protelos/Osseor

Novel FGFR inhibitors disclosed by Incyte Corp.

Scientists at Boehringer Ingelheim divulge novel BTK inhibitors

Janssen begins phase III CREDENCE study of canagliflozin in diabetic nephropathy

New vasopressin V1b receptor antagonists patented by Japanese group

Isis Pharmaceuticals reports data on ISIS-SMNRx in children with spinal muscular atrophy

Bristol-Myers Squibb discloses new agents for HIV infection

Cathepsin G detrimental in a subset of mice with ischemic stroke

Emergent BioSolutions' acquisition of Cangene complete

New phase Ib study evaluates ONT-380 with Kadcyla in metastatic HER2-positive breast cancer

Tender offer for NuPathe shares completed by Teva Pharmaceutical

FDA extends PDUFA action date for Ruconest

FDA extends approval of Kalydeco for cystic fibrosis mutations

Dosing completed in phase II trial of GCS-100 for chronic kidney disease

FDA grants 3-year exclusivity to Vascepa

Jazz Pharmaceuticals completes tender offer for Gentium shares

FTY-720 show anti-inflammatory effects on cerebral ischemia-reperfusion in vivo

Intra-arterial verapamil demonstrates neuroprotective properties in ischemic stroke model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...